CEO David Veitch describes the news and expands on the success of Basilea's business model.

Martin Welschof describes this target that BioInvent is at the forefront of, including single agent data they have seen, and covers other...

He introduces us to Pareto and the conference, and highlights BioInvent, Oculis, Camurus, Vicore Pharma, and Calliditas.

Johan Hartman introduces us to the Karolinska Institute, where his company has benefitted from its Innovations arm, and describes how...

CEO Christian Rohlff describes the expertise the company has build and describes pipeline assets, including partnerships with Boehringer,...

New CEO Mark Bodmer describes the value in understanding the non-coding region of the genome and how he thinks Nucleome is in a unique...

He describes keys such as having a U.S. listing, keeping powerpoint presentations concise, and following the actions of a peer group.

CEO Iain Kilty describes the keys to intervening in cell metabolism, and discusses pipeline assets such as a PKM2 for atopic dermatitis...

Managing Director Luis Mora walks us through the company's development process, from divers in the ocean, to sample testing, and...

Co-Founder & CEO Miquel Vila-Perelló describes the rationale for protein splicing , how it works, and he shares an overview of the...

Martha Lawrence's company has databases on women in pain and maternal health in pain. She explains how customers such as the government...

He covers presentations from Incyte, Genmab, Amgen, and Bristol Myers.

She describes the areas of women's health her firm is focused on, and the importance of getting payers on board.

Marc Stapley explains how the company's Decipher Prostate Test, already successful commercially in localized prostate cancer, could help...

CEO Hervé Hoppenot describes the strategy for Incyte's PD1, and developing the CDK2 for ovarian and endometrial cancers, and possibly...

He discusses data from the Nectin-4 targeting zelenectide pevedotin program, Nectin-4 + CD137, and EphA2.

John Lewis describes the limitations of AAV and LNPs, and how the Entos construct is meant overcome them. Plus, a summary of the...

He highlights things to watch at this year's conference such as PD1xVEGF, PRMT5, TIGIT, and numerous ADCs.

Rajesh Kumar, HSBC's head of life sciences and healthcare equity research in London, talks Merck, Roche, Novo Nordisk, Lilly, Bayer, and...

Danny Bar-Zohar describes Merck KGaA's three pillars of healthcare research: oncology, neurology, and immunology. Plus, the advantages of...